Randomized, Double-Blind Study of the Pharmacokinetics and Safety of Palivizumab Liquid Formulation Compared with Lyophilized Formulation

Infectious Diseases and Therapy

Volumn 3, Issue 2, 2014, Pages 203-214

  Robbie, Gabriel J ^a   Makari, Doris ^a   Harris, Brian ^a   Losonsky, Genevieve A ^a   Jafri, Hasan S ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

Bioequivalence; Liquid; Lyophilized; Palivizumab; Pharmacokinetics; Safety

Indexed keywords

PALIVIZUMAB;

ARTICLE; BIOEQUIVALENCE; BLOOD ANALYSIS; CLINICAL TRIAL; CONJUNCTIVITIS; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG FORMULATION; DRUG SAFETY; EMOTIONAL DISORDER; FEMALE; FEVER; FOLLOW UP; FREEZE DRYING; GASTROINTESTINAL DISEASE; HERNIA; HUMAN; INFANT; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; NEWBORN; OTITIS MEDIA; PAIN; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; RASH; RHINITIS; STATISTICAL ANALYSIS; THRUSH; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

EID: 84977109966     PISSN: 21938229     EISSN: 21936382     Source Type: Journal    
DOI: 10.1007/s40121-014-0042-x     Document Type: Article

References (14)

1. Nair H, Nokes DJ, Gessner BD, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet. 2010;375:1545–55.
2. Committee on Infectious Diseases. From the American Academy of Pediatrics: policy statements–modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics. 2009;124:1694–701.
3. Meissner HC, Long SS, American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics. 2003;112:1447–52.
4. American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics. 2003;112:1442–6.
5. Mejias A, Chavez-Bueno S, Sanchez PJ. Respiratory syncytial virus prophylaxis. Neoreviews. 2005;6:e26–31.
6. Blanken MO, Rovers MM, Molenaar JM, et al. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. N Engl J Med. 2013;368:1791–9.
7. Feltes TF, Cabalka AK, Meissner HC, et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr. 2003;143:532–40.
8. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics. 1998;102:531–7.
9. Data on File—Study MI-CP080. MedImmune, LLC. Gaithersburg.
10. Subramanian KN, Weisman LE, Rhodes T, et al. Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group. Pediatr Infect Dis J. 1998;17:110–5.
11. Abarca K, Jung E, Fernandez P, et al. Safety, tolerability, pharmacokinetics, and immunogenicity of motavizumab, a humanized, enhanced-potency monoclonal antibody for the prevention of respiratory syncytial virus infection in at-risk children. Pediatr Infect Dis J. 2009;28:267–72.
12. Robbie GJ, Zhao L, Mondick J, Losonsky G, Roskos LK. Population pharmacokinetics of palivizumab, a humanized anti-respiratory syncytial virus monoclonal antibody, in adults and children. Antimicrob Agents Chemother. 2012;56:4927–36.
13. Fernandez P, Trenholme A, Abarca K, et al. A phase 2, randomized, double-blind safety and pharmacokinetic assessment of respiratory syncytial virus (RSV) prophylaxis with motavizumab and palivizumab administered in the same season. BMC Pediatr. 2010;10:38.
14. Carbonell-Estrany X, Simoes EA, Dagan R, et al. Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial. Pediatrics. 2010;125:e35–51.